Clinical Trial

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)

Name: Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) — clinical trial record (NCT07739914)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALTERNATION

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.

Trial Details

NCT Number	NCT07739914
Lead Sponsor	Hannover Medical School Collaborators: Royal Infirmary of Edinburgh
Conditions	Liver Allograft, Liver Diseases, Liver Transplantation
Enrollment	150 participants
Start Date	2026-06-30
Primary Completion	2029-06-30 (estimated)
Study Completion	2031-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-31